TOP > 外国特許検索 > METHOD FOR MATURING CARDIOMYOCYTE, METHOD FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, METHOD FOR PURIFYING MATURE CARDIOMYOCYTE, METHOD FOR ASSISTING DRUG DEVELOPMENT, METHOD FOR TREATING HEART DISEASE, MATURE CARDIOMYOCYTE MARKER, REPORTER CELL, MATURE CARDIOMYOCYTE, DEVICE FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, PROGRAM FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, KIT FOR MATURING CARDIOMYOCYTE, AND KIT FOR PURIFYING CARDIOMYOCYTE

METHOD FOR MATURING CARDIOMYOCYTE, METHOD FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, METHOD FOR PURIFYING MATURE CARDIOMYOCYTE, METHOD FOR ASSISTING DRUG DEVELOPMENT, METHOD FOR TREATING HEART DISEASE, MATURE CARDIOMYOCYTE MARKER, REPORTER CELL, MATURE CARDIOMYOCYTE, DEVICE FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, PROGRAM FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, KIT FOR MATURING CARDIOMYOCYTE, AND KIT FOR PURIFYING CARDIOMYOCYTE

Foreign code F210010486
File No. (S2020-0096-N0)
Posted date 2021年7月29日
Country 世界知的所有権機関(WIPO)
International application number 2020JP044816
International publication number WO 2021112115
Date of international filing 令和2年12月2日(2020.12.2)
Date of international publication 令和3年6月10日(2021.6.10)
Priority data
  • 特願2019-218998 (2019.12.3) JP
Title METHOD FOR MATURING CARDIOMYOCYTE, METHOD FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, METHOD FOR PURIFYING MATURE CARDIOMYOCYTE, METHOD FOR ASSISTING DRUG DEVELOPMENT, METHOD FOR TREATING HEART DISEASE, MATURE CARDIOMYOCYTE MARKER, REPORTER CELL, MATURE CARDIOMYOCYTE, DEVICE FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, PROGRAM FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, KIT FOR MATURING CARDIOMYOCYTE, AND KIT FOR PURIFYING CARDIOMYOCYTE
Abstract Provided is a method for maturing a cardiomyocyte, whereby it becomes possible to obtain a maturated mature cardiomyocyte. One component selected from the group consisting of a specific nuclear receptor agonist, a maturation-promoting compound and a transcriptional factor capable of promoting the maturation of a cardiomyocyte or an arbitrary combination of these components is added to an immature cardiomyocyte. As a result, the immature cardiomyocyte can be matured to give a mature cardiomyocyte. Among the above-mentioned components, a nuclear receptor agonist is one component selected from the group consisting of a hormone, an RXR agonist, a PPAR agonist and an ROR agonist or an arbitrary combination of these components, and the maturation-promoting compound is an HIF1a inhibitor.
Outline of related art and contending technology BACKGROUND ART
According to the statistical investigation of the Japan Lifestyle-related Disease Prevention Association (JPALD), the total number of patients with cardiac diseases such as cardiomyopathy and the like that develop particularly after adults was 172 million 9000 April 19, (2016), the number of annual death of ischemic cardiac disease; "Acute myocardial infarction" 30,000 7222, "Other ischemic heart disease" 30,000 4451, with heart disease mortality reported as 19 million 6113 annually. Also, ischemic heart disease involving myocardial infarction costs 7,503 billion yen, which accounts for 5630 billion yen over 65 years of age (2015). It is expected that this will increase further as the aging progresses.
Regenerative medicine has been considered for the treatment of such cardiac diseases. For example, by inducing differentiation of pluripotent stem cells such as ES cells (Embryonic Stem Cell) or iPS cells (induced Pluripotent Stem cells) to produce cardiomyocytes, and implanting the cardiomyocytes, it is thought that the cardiomyocytes can be treated ten times. Furthermore, techniques for analyzing cardiac diseases and evaluating drug toxicity by using cardiomyocytes produced by inducing differentiation are also anticipated.
For example, Patent Document 1 describes a method for producing a differentiated and mature cardiomyocyte by culturing a stem cell as a raw material cell, the method comprising transiently co-expressing a Sall1 gene and a Mesp1 gene in the cultured cell.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JICHI MEDICAL UNIVERSITY
  • Inventor
  • UOSAKI, Hideki
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close